ArticleAdvances in neurobiology2023
Gangliosides in Neurodegenerative Diseases.
Article in Advances in neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Sphingolipids in Gaucher disease: a systematic review.Orphanet journal of rare diseases · 2025Pooled it
- Dose- and state-dependent enhancement of hippocampal CA1 pyramidal neuron excitability by GM1 ganglioside in male rats with cholinergic lesions.Scientific reports · 2026Article
- Ganglioside sialylation modulates tau internalization and pathology spread.Molecular psychiatry · 2026Article
- Forgotten Gangliosides:International journal of molecular sciences · 2026Review
- Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.International journal of molecular sciences · 2024Review
- Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers.International journal of molecular sciences · 2024Review
- An open chat with… Sandro Sonnino.FEBS open bio · 2023Article
- Synthetic GM1 improves motor and memory dysfunctions in mice with monoallelic or biallelic disruption of GM3 synthase.FEBS open bio · 2023Article
- Lipid rafts and human diseases: why we need to target gangliosides.FEBS open bio · 2023Review
- Uncovering the Lipid Web: Discovering the Multifaceted Roles of Lipids in Human Diseases and Therapeutic Opportunities.International journal of molecular sciences · 2023Article
- Article
- Age-Related Decline in Gangliosides GM1 and GD1a in Non-CNS Tissues of Normal Mice: Implications for Peripheral Symptoms of Parkinson's Disease.Biomedicines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main purpose of this chapter is to summarize the chief findings on ganglioside changes/interactions with some of the neurodegenerative disorders. For the latter we have focused on three diseases that have seen especially intensive study in that regard: Parkinson's, Alzheimer's, and Huntington's diseases. Parkinson's disease (PD) has received the most intensive study with revelation of systemic deficiency of GM1 in brain and all peripheral tissues that have been analyzed to date; this pointed to GM1 replacement as a promising therapy which proved only partially successful when tried for reasons that are discussed. Huntington's disease resembles PD in also manifesting GM1 deficiency, which did, however, respond to GM1 replacement therapy - apparently due to GM1 being administered directly into the brain. Alzheimer's disease was more complex in relation to gangliosides, with b-series (GD1b, GT1b) apparently depressed along with a-series. GM1 administered in brain appeared to induce improvement, but in a limited number of patients. We summarize studies showing why GM1 is of critical importance in neuronal function, and we also briefly point to a few additional neurological disorders in which one or more ganglioside changes have been implicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.